Literature DB >> 26755086

Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women.

Maurizio Baldassarre1, Stefania Alvisi2, Ilaria Mancini2, Simona Moscatiello3, Giulio Marchesini3, Renato Seracchioli2, Maria Cristina Meriggiola4.   

Abstract

INTRODUCTION: Dyslipidemia is a common risk factor for cardiovascular disease which may contribute to sexual dysfunction in women. AIMS: To assess the impact of dyslipidemia compared with other metabolic alterations on female sexual function.
METHODS: In total, 466 women were enrolled in the study, of which 256 were postmenopausal. Dyslipidemia was defined based on high-density lipoprotein, low-density lipoprotein, or triglycerides levels. Women completed the Female Sexual Function Index (FSFI), the Female Sexual Distress Scale (FSDS), and the Middlesex Hospital Questionnaire (MHQ). Biochemical and anthropometric measurements were performed and the Framingham risk score (FRS) was calculated for each subject. MAIN OUTCOME MEASUREMENTS: FSFI, FSDS, and MHQ scores, prevalence of FSD and FRS.
RESULTS: Median age of the population enrolled was 51.5 (range 42.0-58.0) years. The overall prevalence of FSD, according to FSFI and FSDS scores, was 24%. A significantly higher prevalence of FSFI (P = .001) and FSDS (P = .006) pathological scores were found in women with dyslipidemia compared with the control group. The prevalence of FSD was significantly higher in dyslipidemic women (P = .001). Women with dyslipidemia had significantly higher total scores in areas of depression, somatization, and obsession in the MHQ questionnaire compared with control women. Multivariate analysis showed that dyslipidemia (OR:1.7, CI 1.1-2.9, P = .037), postmenopausal status (OR:2.7, CI 1.5-4.7, P = .001), higher education (OR:0.6; CI 0.3-0.9, P = .038), and somatization (OR:1.7, CI 1.0-2.8, P = .045) were independently associated with FSD. The FRS was higher in dyslipidemic women (P = .001) and in those with FSD (P = .001), being associated with an almost doubled risk of developing FSD.
CONCLUSION: Our results indicate that dyslipidemia is an independent risk factor for FSD irrespective of postmenopausal status. Also, psychopathological alterations such as somatization are strongly associated with sexual dysfunction. The direct correlation between FSFI score and FRS suggest the importance of cardiovascular integrity in female sexual health.
Copyright © 2016 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; Female Sexual Distress Scale; Female Sexual Dysfunction; Female Sexual Function Index; Framingham risk score; Middlesex Hospital Questionnaire

Mesh:

Year:  2016        PMID: 26755086     DOI: 10.1016/j.jsxm.2015.11.005

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  5 in total

Review 1.  The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review.

Authors:  Simona Di Francesco; Marika Caruso; Iole Robuffo; Andrea Militello; Elena Toniato
Journal:  Curr Urol       Date:  2019-03-08

Review 2.  "Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial".

Authors:  Van T Hoang; Hoang-Phuong Nguyen; Viet Nhan Nguyen; Duc M Hoang; Tan-Sinh Thi Nguyen; Liem Nguyen Thanh
Journal:  Front Cell Dev Biol       Date:  2022-09-28

3.  How Is the Sexual Function of Premenopausal Chinese Women Without Hyperlipidemia?

Authors:  Yali Xiang; Yuxin Tang; Jiaqun Li; Dongjie Li
Journal:  Sex Med       Date:  2019-12-16       Impact factor: 2.491

4.  Prevalence of Sexual Dysfunction in Women with Type 1, 2 Diabetes and Thyroid Disorder: A Cross-Sectional Study in Taif City, Saudi Arabia.

Authors:  Khalid M Alshehri; Raghad A Althobaiti; Athar I Alqurashi; Nada E Algethami; Khaled A Alswat
Journal:  Int J Womens Health       Date:  2022-03-17

5.  Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome.

Authors:  Małgorzata Kałużna; Agnieszka Nomejko; Aleksandra Słowińska; Katarzyna Wachowiak-Ochmańska; Katarzyna Pikosz; Katarzyna Ziemnicka; Marek Ruchała
Journal:  Endocr Connect       Date:  2021-08-30       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.